Dynavax Technologies Corp. (DVAX) Friday reported a wider fourth-quarter net loss of $20.5 million or $0.11 per share, compared to $4.3 million or $0.03 per share last year. Analysts polled by Thomson Reuters estimated loss of $0.08 per share. Analyst estimates typically exclude one-time items.
Revenues for the quarter was dropped to $1.8 million from $11.4 million last year. Dynavax said its collaboration revenue last year was higher due to the recognition of certain milestones achieved under Dynavax's partnership with GlaxoSmithKline. Analysts estimated revenues of $6.91 million for the period.
Research and development expenses increased to $12.5 million from $11.6 million last year, due to growth in the organization associated with manufacturing and regulatory activities for Heplisav.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.